Anti-Alzheimer's disease compound
Through the structural transformation of the saponin of Jinyingzi, compounds with stronger anti-Alzheimer's activity were prepared, which solved the problems of limited effects of existing drugs and complex production processes, and achieved effective inhibition and control in in vitro experiments and Neurocellular protection, suitable for industrial production.
Patent Information
- Application Number
- CN202411020388.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-12-03
AI Technical Summary
The existing anti-Alzheimer's drugs have limited effects and are complex in industrial production, making them difficult to apply on a large scale.
By transforming the structure of the saponin of the saponin of the saponin of the 28-position COOH structure was prepared, and the 28-position COOH structure was optimized through chemical synthesis. The gentle reaction conditions and simple process were used to obtain stronger resistance to the Alzheimer New compounds that are active in Silty.
The new compound showed effective inhibition and neuronal protection effects on acetylcholinesterase in in vitro experiments, and had potential effects on the treatment of Alzheimer's disease. It has a simple synthetic method and is suitable for industrial production.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to a medicinal compound, in particular to an anti-Alzheimer's disease compound. Background Art
[0002] Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Patients will gradually lose their cognitive, behavioral, memory and learning abilities. AD mainly affects the elderly. The disease usually develops in middle and late adulthood. Due to the aging of the population worldwide, the disease is reaching epidemic proportions and will impose a huge burden on humans, society and the economy. As an irreversible neurodegenerative brain disease, AD is a rare and degenerative disease.
[0003] Rosa laevigata sapogenin (RLMS, 2α, 3β, 19α, 23-tetrahydroxy-12-ene-28-oicacid) is a pentacyclic triterpenoid compound extracted from the Rosa laevigata plant. Rosa laevigata triterpenoid compounds have potential anti-Alzheimer's disease, anti-inflammatory, and kidney protection effects. SooJungChol et al. found that the active ingredients in the Rosa laevigata alcohol extract inhibit the cytotoxicity of Aβ produced in neuronal cell oxidative stress, improve cell survival rate, and have a certain anti-Alzheimer's effect (AMYLOID, 2006 Vol. 13 No. 1); Gao Pinyi et al. found that the triterpenoid compounds extracted from Rosa laevigata have anti-acetylcholinesterase and neuronal cell protective activity, showing a certain anti-Alzheimer's effect (RSC Advances, 2018 Vol. 8 No. 67). Summary of the invention
[0004] The purpose of the present invention is to provide a compound for resisting Alzheimer's disease, and the present invention aims to develop a new compound for resisting Alzheimer's disease. The synthesis method of various types of modified sapogenins of the present invention is simple, the reaction conditions are mild, the operation is easy, and it is suitable for industrial production.
[0005] The objective of the present invention is achieved through the following technical solutions:
[0006] The compound of the invention which is structurally modified with Rosa laevigata sapogenin is prepared by a chemical synthesis method with Rosa laevigata sapogenin as a parent body, and is a new RLMS derivative with structurally modified COOH at position 28, and its anti-Alzheimer's activity is explored by in vitro activity verification.
[0007] The chemical structural formula of the Rosa laevigata sapogenin parent is:
[0008]
[0009] The above-mentioned 28-position COOH of the sapogenin derivative is connected to a new substituent, and its structural formula is any one of the following:
[0010]
[0011]
[0012] The preparation method of various types of rosa laevigata sapogenin structure-modified compounds of the present invention is as follows: dissolving in 1-2 mL of DMF, reacting rosa laevigata sapogenin with a reagent at a ratio of 1:1.5-2.5 at 0-35° C. for 0-1 h, separating the products by column chromatography to obtain the rosa laevigata sapogenin structure-modified compounds.
[0013] The preferred preparation method of various types of modified products of the sapogenin structure of the present invention is as follows: in 1 mL of DMF solvent, under stirring at 30° C., sapogenin and a reagent are reacted at a ratio of 1:2 for 0.5 h, and the product is separated by column chromatography to obtain a sapogenin structure-modified compound.
[0014] The reagents described in the present invention can be selected from conventional reagents according to the structural characteristics of the compounds.
[0015] The advantages and effects of the present invention are:
[0016] The invention discloses an application of various types of modified structures of Rosa laevigata sapogenin in preparing drugs for treating Alzheimer's disease.
[0017] The various types of modified structures of Rosa laevigata sapogenin of the present invention have better or similar anti-Alzheimer's activity than Rosa laevigata sapogenin. The synthesis method of the various types of modified structures of Rosa laevigata sapogenin of the present invention is simple, the reaction conditions are mild, the operation is easy, and the method is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] Figure 1 for the neuroprotective effects of compounds 1-14 against H2O2-induced injury in SH-SY5Y;
[0019] Figure 2 For. Molecular dynamics simulation;
[0020] Figure 3 is the mass spectrum of compound 1;
[0021] Figure 4 is the H NMR spectrum of compound 1;
[0022] Figure 5 is the carbon spectrum of compound 1;
[0023] Figure 6 is the mass spectrum of compound 2;
[0024] Figure 7is the H NMR spectrum of compound 2;
[0025] Figure 8 is the carbon spectrum of compound 2;
[0026] Fig. 9 is the mass spectrum of compound 3;
[0027] Fig.10 is the H NMR spectrum of compound 3;
[0028] Fig.11 is the carbon spectrum of compound 3;
[0029] Fig.12 is the mass spectrum of compound 4;
[0030] Fig.13 is the H NMR spectrum of compound 4;
[0031] Fig.14 is the carbon spectrum of compound 4;
[0032] Fig.15 is the mass spectrum of compound 5;
[0033] Fig.16 is the H NMR spectrum of compound 5;
[0034] Fig.17 is the carbon spectrum of compound 5;
[0035] Fig.18 is the mass spectrum of compound 6;
[0036] Fig.19 is the H NMR spectrum of compound 6;
[0037] Fig. 20 is the carbon spectrum of compound 6;
[0038] Fig.21 is the mass spectrum of compound 7;
[0039] Fig. 22 is the H NMR spectrum of compound 7;
[0040] Fig.23 is the carbon spectrum of compound 7;
[0041] Fig.24 is the mass spectrum of compound 8;
[0042] Fig.25 is the H NMR spectrum of compound 8;
[0043] Fig.26 is the carbon spectrum of compound 8;
[0044] Fig. 27 is the mass spectrum of compound 9;
[0045] Fig.28 is the H NMR spectrum of compound 9;
[0046] Fig.29 is the carbon spectrum of compound 9;
[0047] Fig.30 is the mass spectrum of compound 10;
[0048] Fig.31 is the H NMR spectrum of compound 10;
[0049] Fig.32 is the carbon spectrum of compound 10;
[0050] Fig.33 is the mass spectrum of compound 11;
[0051] Fig.34 is the H NMR spectrum of compound 11;
[0052] Fig.35 is the carbon spectrum of compound 11;
[0053] Fig.36 is the mass spectrum of compound 12;
[0054] Fig.37 is the H NMR spectrum of compound 12;
[0055] Fig.38 is the carbon spectrum of compound 12;
[0056] Fig.39 is the mass spectrum of compound 13;
[0057] Fig.40 is the H NMR spectrum of compound 13;
[0058] Fig.41 is the carbon spectrum of compound 13;
[0059] Fig.42 is the mass spectrum of compound 14;
[0060] Fig.43 is the H NMR spectrum of compound 14;
[0061] Fig.44 This is the carbon spectrum of compound 14. DETAILED DESCRIPTION
[0062] The following experiments and examples are intended to further illustrate but not limit the present invention.
[0063] Experimental Example 1 Direct target experiment on 14 kinds of modified products of rosa laevigata sapogenin
[0064] The Ellman method was used to explore the in vitro inhibitory effects of the 14 structural modifications of the above-mentioned Rosa laevigata sapogenin on AChE. Galanthamine was used as a positive drug for comparative analysis, as shown in Table 1.
[0065] Table 1. Cholinesterase inhibitory activity of compounds 1-14, RLMS and Galanthamine
[0066]
[0067]
[0068] The results showed that among the 14 compounds in the experiment, compound 4 showed the most effective inhibitory activity against AChE.
[0069] To further study the interaction of compounds 1-14 with AChE, we used molecular docking software for analysis. In this experiment, the Autodock4.2 package was used. We selected the X-ray crystal structure of AChE (PDBid: 1W6R) from the Brookhaven database, and extracted the binding point (X: 3.777, Y: 66.192, Z: 64.342) and size (8.599 × 8.599 × 8.599) of the cocrystal ligand galanthamine in the docking. The experiment superimposed the minimum ligand on the receptor, performed 14 runs to obtain the 5 optimal conformations, and all other parameters were set to default values. The data results can be seen in Table 2.
[0070] Table 2. Binding energy of 14 compounds to receptor (1W6R)
[0071]
[0072] The results show that the binding energies of compounds 1-14 are all lower than that of RLMS, among which compound 14 exhibits the best binding energy and has potential therapeutic activity against AD.
[0073] Experimental Example 2: Experimental study on the neuron protection activity of 14 kinds of modified products of Rosa laevigata sapogenin
[0074] The MTT method was used to analyze the neuroprotective effects of 14 kinds of modified sapogenins of Rosa laevigata on H2O2-induced injury in SH-SY5Y cells. Figure 1 . Figure 1 Neuroprotective effects of compounds 1-14 on H2O2-induced injury in SH-SY5Y cells
[0075] The results showed that compounds 5, 6, 9, 10, and 13 showed moderate neuroprotective activity at a concentration of 25 μL, and compounds 4, 8, 12, and 14 showed significant neuroprotective activity.
[0076] Experimental Example 3 Molecular dynamics simulation
[0077] We selected compound 4 with good experimental results in Experimental Examples 1 and 2 for molecular dynamics simulation analysis, and used OPLS-2005 force field to perform MD simulation at 100 ns. (The left Y axis represents protein RMSD, and the right Y axis represents ligand RMSD). The results are shown in Figure 2 ; Figure 2 .Molecular dynamics simulation.
[0078] It can be seen from the figure that compound 4 has good stability with AChE.
[0079] The following examples can achieve the above effects
[0080] Embodiment 1:
[0081] Synthesis of compound 1:
[0082] RLMS (50 mg) and DMAP (19 mg, 1.5 eq) were weighed in sequence and added to a 25 mL single-mouth round-bottom flask, and DMF (2 mL) was added to dissolve it, and the mixture was placed in an oil bath and stirred at 30 ° C. PyBOP (103 mg, 2 eq), DIPEA (33 μL, 2 eq) and 2-fluorobenzylamine (23 μL, 2 eq) were then added in sequence. The reaction was continued for 0.5 h, and the completion of the reaction was detected by TLC. The developing solvent was dichloromethane: methanol = 10: 1 (v / v). After the reaction was completed, 50 mL of water was added, and the mixture was extracted with ethyl acetate 3 times. The organic layer was dried by rotary evaporation. The product was purified by silica gel column chromatography, and the eluent was petroleum ether: ethyl acetate = 2: 1 to 1: 3 (v / v), and compound 1 (17 mg) was finally obtained.
[0083] The structure of compound 1 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Figure 3 , Figure 4 and Figure 5 , the characterization data are as follows:
[0084] MS (m / z): 634.4 [M+H] + .
[0085] 1 H-NMR (600MHz, C5D5N):δ H8.20(1H,d,J=8.4Hz),7.62-7.74(2H,m),7.42(1H,t,J=7.7Hz),6.30(1H,s),6.05(1H, s),5.81(1H,s),5.59(1H,s),5.50(1H,s),4.21-4.30(4H,m),3.75(1H,d,J=10.0Hz),3. 26(1H,dt,J=13.6,4.3Hz),2.79(1H,s),2.27-2.34(3H,m),1.97-2.21(11H,m),1.64(3 H,s),1.41-1.56(6H,m),1.37(3H,s),1.14(3H,d,J=6.42Hz),1.11(6H,s),1.09(3H,s).
[0086] 13 C-NMR (150MHz, C5D5N):δ C 178.7,160.9,140.4,130.8,129.5,128.5,128.1,124.9,115.9,78.6,73.0,69.3,66.8,54.9,50.2,48.0,44.7,44.1,42.6,42.3,40.5,38.8,38.4,37.8,34.8,33.6,29.8,29.3,27.0,26.4,25.0,24.6,19.0,18.2,7.8,17.0,14.8.
[0087] Embodiment 2:
[0088] Synthesis of compound 2:
[0089] 2-fluorobenzylamine was replaced with 3-fluorobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether: ethyl acetate = 2:1 to 1:3 (v / v) to finally obtain compound 2 (15 mg).
[0090] The structure of compound 2 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Figure 6 , Figure 7 and Figure 8 , the characterization data are as follows:
[0091] MS (m / z): 634.4 [M+H] + .
[0092] 1 H-NMR (600MHz, C5D5N):δ H8.20(1H,d,J=8.4Hz),7.71(1H,d,J=8.3Hz),7.27-7.35(2H,m),6.30(1H,s),6.04(1H ,s),5.80(1H,s),5.58(1H,s),5.50(1H,s),4.21-4.29(4H,m),3.75(1H,d,J=8.6Hz),3 .26(1H,dt,J=13.6,4.3Hz),2.79(1H,s),2.27-2.34(2H,m),1.97-2.22(9H,m),1.64(3 H,s),1.40-1.57(5H,m),1.37(3H,s),1.17(3H,d,J=8.6Hz),1.11(6H,s),1.09(3H,s).
[0093] 13 C-NMR (150MHz, C5D5N):δ C 178.7,162.9,144.5,140.4,128.6,125.6,121.1,115.3,114.1,78.6,73.0,69.3,66.8,54.8,50.2,48.0,44.0,43.5,42.7,42.5,42.3,39.7,38.7,36.3,34.9,33.5,29.3,28.7,27.0,26.4,25.0,24.6,19.0,18.2,17.8,17.0,14.8
[0094] Embodiment 3:
[0095] Synthesis of compound 3:
[0096] 2-Fluorobenzylamine was replaced with 4-fluorobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 3 (13.5 mg).
[0097] The structure of compound 3 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig. 9 , Fig.10 and Fig.11 , the characterization data are as follows:
[0098] MS (m / z): 634.4 [M+H] + .
[0099] 1 H-NMR (600MHz, C5D5N):δ H7.71(1H,d,J=8.0Hz),7.49(1H,t,J=5.8Hz),7.42(1H,t,J=7.8Hz),7.14(1H,t,J=8.5Hz) ,6.29(1H,s),6.05(1H,s),5.80(1H,s),5.50(1H,s),4.23-4.30(3H,m),3.75(1H,d,J=9.5 Hz),3.16(1H,dt,J=13.2,3.9Hz),2.95(1H,s),2.28-2.34(2H,m),1.96-2.21(9H,m),1.6 4(3H,s),1.42-1.57(5H,m),1.37(3H,s),1.17(3H,d,J=5.1Hz),1.11(6H,s),1.09(3H,s).
[0100] 13 C-NMR (150MHz, C5D5N):δ C 178.5,161.7,140.5,130.3,129.9,129.8,128.5,115.8,115.7,78.7,73.2,69.3,66.9,54.8,50.2,48.0,44.0,43.3,42.7,42.5,42.3,40.9,39.6,38.8,33.5,29.8,29.3,27.4,27.0,26.4,25.0,24.6,19.1,18.2,17.8,17.2,14.8.
[0101] Embodiment 4:
[0102] The common name of compound 4:
[0103] 2-Fluorobenzylamine was replaced with 2-chlorobenzylamine, and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography, and the eluent was: petroleum ether: ethyl acetate = 2:1 to 1:3 (v / v), and finally compound 4 (20 mg) was obtained.
[0104] The structure of compound 4 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.12 , Fig.13 and Fig.14 , the characterization data are as follows:
[0105] MS (m / z): 650.4 [M+H] + .
[0106] 1 H-NMR (600MHz, C5D5N):δ H8.20(1H,d,J=8.4Hz),7.71(1H,d,J=8.3Hz),7.42(1H,d,J=7.7Hz),7.25-7.31(1H,m),6.30 (1H,s),6.05(1H,s),5.81(1H,s),5.58(1H,s),5.50(1H,s),4.21-4.29(4H,m),3.75(1H,d,J =10.2Hz),3.26(1H,dt,J=13.6,4.3Hz),2.79(1H,s),2.27-2.35(3H,m),1.97-2.20(9H,m),1 .64(3H,s),1.40-1.48(5H,m),1.37(3H,s),1.14(3H,d,J=6.5Hz),1.11(6H,s),1.09(3H,s).
[0107] 13 C-NMR (150MHz, C5D5N):δ C 178.6,144.5,140.4,132.9,129.7,129.5,129.1,128.4,125.6,78.7,73.3,69.3,66.9,54.7,50.1,48.0,44.7,42.6,42.5,42.3,40.9,39.6,38.4,36.0,33.5,33.4,29.0,28.7,27.5,27.0,26.4,24.6,19.0,18.2,17.8,17.1,14.8.
[0108] Embodiment 5:
[0109] Synthesis of compound 5:
[0110] 2-Fluorobenzylamine was replaced with 3-chlorobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 5 (14 mg).
[0111] The structure of compound 5 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.15 , Fig.16 and Fig.17 , the characterization data are as follows:
[0112] MS (m / z): 650.4 [M+Na] + .
[0113] 1 H-NMR (600MHz, C5D5N):δ H7.71(1H,d,J=8.7Hz),7.65(1H,t,J=7.2Hz),7.42(1H,t,J=7.6Hz),7.31(1H,t,J=7.6Hz),6. 31(1H,s),6.04(1H,s),5.83(1H,s),5.58(1H,s),5.50(1H,s),4.22-4.29(4H,m),3.75(1H,d ,J=7.6Hz),3.26(1H,dt,J=13.7,4.3Hz),2.94(1H,s),2.29-2.34(3H,m),2.02-2.30(9H,m), 1.64(3H,s),1.38-1.57(5H,m),1.38(3H,s),1.14(3H,d,J=6.4Hz),1.11(6H,s),1.09(3H,s).
[0114] 13 C-NMR (150MHz, C5D5N):δ C 178.7,144.5,140.4,133.9,130.3,130.1,128.6,127.7,125.6,78.6,72.3,69.8,66.8,54.8,50.1,48.0,44.0,42.6,42.5,42.3,41.9,40.8,38.7,38.5,33.5,29.8,29.2,27.4,27.0,26.4,25.0,24.6,18.2,17.8,17.6,17.1,14.7.
[0115] Embodiment 6:
[0116] Synthesis of compound 6:
[0117] 2-Fluorobenzylamine was replaced with 4-chlorobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 6 (13 mg).
[0118] The structure of compound 6 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.18 , Fig.19 and Fig. 20 , the characterization data are as follows:
[0119] MS (m / z): 650.4 [M+Na] + .
[0120] 1 H-NMR (600MHz, C5D5N):δ H8.20(1H,d,J=8.4Hz),7.71(1H,d,J=8.3Hz),7.64(1H,t,J=7.3Hz),7.42(1H,d,J=7.7Hz),6.30(1 H,s),6.05(1H,s),5.81(1H,s),5.59(1H,s),5.50(1H,s),4.21-4.30(4H,m),3.75(1H,d,J=9.8Hz) ,3.26(1H,dt,J=13.6,4.3Hz),2.79(1H,s),2.28-2.34(3H,m),2.10-2.19(8H,m),1.77-1.89(4H, s),1.65(3H,s),1.41-1.50(5H,m),1.37(3H,s),1.14(3H,d,J=6.48Hz),1.11(6H,s),1.09(3H,s).
[0121] 13 C-NMR (150MHz, C5D5N):δ C 178.7,140.4,138.4,134.6,129.9,129.8,128.6,128.6,128.6,78.6,72.9,69.3,66.8,54.9,50.2,48.0,44.6,44.1,43.5,42.7,42.3,39.7,38.7,36.0,34.8,33.6,29.8,29.3,27.4,26.4,25.0,24.6,19.0,18.2,17.8,17.0,14.8.
[0122] Embodiment 7:
[0123] Synthesis of compound 7:
[0124] 2-Fluorobenzylamine was replaced with 2-bromobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 7 (11 mg).
[0125] The structure of compound 7 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.21 , Fig. 22 and Fig.23 , the characterization data are as follows:
[0126] MS (m / z): 694.3 [M+Na] + .
[0127] 1H-NMR (600MHz, C5D5N):δ H 8.20(1H,d,J=8.4Hz),7.71(1H,d,J=8.3Hz),7.65(1H,t,J=7.3Hz),7.43(1H,t,J=7 .7Hz),5.58(1H,s),5.50(1H,s),4.20-4.29(3H,m),3.75(1H,d,J=10.4Hz),3.26(1 H,t,J=13.6,4.3Hz),2.79(1H,s),2.27-2.34(2H,m),2.01-2.19(8H,m),1.65(3H,s ),1.43-1.57(5H,m),1.37(3H,s),1.14(3H,d,J=3.5Hz),1.11(6H,s),1.09(3H,s).
[0128] 13 C-NMR (150MHz, C5D5N):δ C 178.7,144.5,140.5,133.2,129.5,129.3,128.7,128.2,121.0,78.6,72.9,69.2,66.9,54.9,50.1,48.5,44.0,42.6,42.3,40.9,40.8,38.7,38.5,36.0,33.5,33.4,29.8,29.2,27.0,26.4,25.0,24.6,19.0,18.2,17.8,17.0,14.7.
[0129] Embodiment 8:
[0130] Synthesis of compound 8:
[0131] 2-Fluorobenzylamine was replaced with 3-bromobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 8 (12 mg).
[0132] The structure of compound 8 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.24 , Fig.25 and Fig.26 , the characterization data are as follows:
[0133] MS (m / z): 694.3 [M+Na] + .
[0134] 1 H-NMR (600MHz, C5D5N):δH 7.73(1H,t,J=4.2Hz),7.65(1H,t,J=7.3Hz),7.41-7.46(2H,m),6.31(1H,s),6.05(1H ,s),5.81(1H,s),5.50(1H,s),5.51(1H,s),4.21-4.28(3H,m),3.76(1H,d,J=7.6Hz),3 .26(1H,t,J=13.5,4.1Hz),2.79(1H,s),2.28-2.35(2H,m),2.00-2.20(8H,m),1.65(3 H,s),1.43-1.57(5H,m),1.38(3H,s),1.14(3H,d,J=6.4Hz),1.12(6H,s),1.10(3H,s).
[0135] 13 C-NMR (150MHz, C5D5N):δ C 178.7,144.0,140.4,131.6,129.8,129.5,128.6,125.6,121.1,78.6,73.0,69.3,66.8,54.9,48.3,48.0,44.1,43.4,42.7,42.3,40.9,39.7,38.7,38.5,33.6,29.8,29.3,27.5,27.0,26.4,25.0,24.6,18.2,17.8,17.1,17.0,14.8.
[0136] Embodiment 9:
[0137] Synthesis of compound 9:
[0138] 2-Fluorobenzylamine was replaced with 4-bromobenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 9 (9 mg).
[0139] The structure of compound 9 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig. 27 , Fig.28 and Fig.29 , the characterization data are as follows:
[0140] MS (m / z): 694.3 [M+Na] + .
[0141] 1 H-NMR (600MHz, C5D5N):δ H7.72(1H,t,J=8.3Hz),7.64(1H,t,J=7.4Hz),7.38-7.44(2H,m),6.30(1H,s),6.05(1H ,s),5.82(1H,s),5.59(1H,s),5.50(1H,s),4.21-4.28(4H,m),3.76(1H,d,J=10.3Hz), 3.26(1H,t,J=13.6,4.1Hz),2.79(1H,s),2.27-2.34(3H,m),2.01-2.19(9H,m),1.64(3 H,s),1.42-1.56(5H,m),1.37(3H,s),1.14(3H,d,J=6.5Hz),1.11(6H,s),1.09(3H,s).
[0142] 13 C-NMR (150MHz, C5D5N):δ C 178.6,140.4,138.5,130.5,130.5,129.9,129.7,128.5,121.1,78.6,73.0,69.3,66.8,54.9,50.2,48.0,44.0,43.4,42.6,42.5,40.9,39.6,38.7,38.5,33.5,29.8,27.5,27.0,26.4,25.0,24.6,24.5,19.0,18.2,17.8,17.0,14.8.
[0143] Embodiment 10:
[0144] Synthesis of compound 10:
[0145] 2-Fluorobenzylamine was replaced with n-hexylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 10 (18 mg).
[0146] The structure of compound 10 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.30 , Fig.31 and Fig.32 , the characterization data are as follows:
[0147] MS (m / z): 610.4 [M+Na] + .
[0148] 1 H-NMR (600MHz, C5D5N):δ H6.29(1H,s),6.04(1H,s),5.80(1H,s),5.59(1H,s),4.21-4.29(3H,m),3.75 (1H,d,J=10.3Hz),3.51-3.57(1H,m),3.26(1H,t,J=13.6,4.0Hz),2.79(1H,s ),2.27-2.35(2H,m),1.96-2.19(8H,m),1.77-1.90(4H,m),1.65(3H,s),1.4 0-1.60(5H,m),1.38(3H,s),1.14(3H,d,J=6.4Hz),1.11(6H,s),1.09(3H,s).
[0149] 13 C-NMR (150MHz, C5D5N):δ C 178.4,140.7,128.4,78.6,73.0,69.3,66.8,54.8,50.1,48.3,44.1,42.7,42.3,40.9,40.5,39.7,38.8,38.5,33.6,32.2,30.4,29.8,29.3,27.7,27.0,26.5,25.0,24.6,24.5,23.3,18.2,17.8,17.2,17.0,14.8,14.6.
[0150] Embodiment 11:
[0151] Synthesis of compound 11:
[0152] 2-Fluorobenzylamine was replaced with cyclohexylbenzylamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 11 (17 mg).
[0153] The structure of compound 11 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.33 , Fig.34 and Fig.35 , the characterization data are as follows:
[0154] MS (m / z): 608.4 [M+Na] + .
[0155] 1 H-NMR (600MHz, C5D5N):δ H6.30(1H,s),6.04(1H,s),5.82(1H,s),5.58(1H,s),5.50(1H,s),4.20-4.2 9(4H,m),3.75(1H,d,J=8.5Hz),3.25(1H,dt,J=13.6,4.2Hz),2.79(1H,s),2 .27-2.34(3H,m),2.02-2.18(7H,m),1.86(1H,d,J=11.6),1.76-1.88(2H,m) ,1.64(3H,s),1.37(3H,s),1.14(3H,d,J=6.4Hz),1.11(6H,s),1.09(3H,s).
[0156] 13 C-NMR (150MHz, C5D5N):δ C 175.1,138.5,129.5,78.6,73.0,69.3,66.8,54.9,50.1,48.3,48.0,44.0,42.6,42.3,40.9,38.8,38.7,38.5,35.8,33.7,33.6,33.6,29.8,27.5,27.0,26.9,26.4,25.0,24.9,24.6,24.5,19.0,18.2,17.8,17.0,14.8.
[0157] Embodiment 12:
[0158] Synthesis of compound 12:
[0159] 2-Fluorobenzylamine was replaced with benzylamine, and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography, and the eluent was: petroleum ether: ethyl acetate = 2: 1 to 1: 3 (v / v), and finally compound 12 (5 mg) was obtained.
[0160] The structure of compound 12 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.36 , Fig.37 and Fig.38 , the characterization data are as follows:
[0161] MS (m / z): 616.4 [M+Na] + .
[0162] 1 H-NMR (600MHz, C5D5N):δ H7.53(2H,d,J=1.6Hz),7.38(2H,t,J=7.6Hz),7.28(1H,t,J=7.4Hz),6.29(1H,s),6.05(1H,s),5.8 0(1H,s),5.50-5.59(2H,m),5.12(1H,s),4.74(2H,d,J=5.1),4.21-4.32(4H,m),3.75(1H,d,J=10. 0Hz),3.17(1H,td,J=13.4,4.4Hz),2.95(1H,s),2.28-2.34(2H,m),1.96-2.24(10H,m),1.87(2H,d ,J=12Hz),1.65(3H,s),1.37(3H,s),1.18(3H,s),1.12(3H,s),1.09(3H,d,J=6.3Hz),1.04(3H,s).
[0163] 13 C-NMR (150MHz, C5D5N):δ C 178.6,140.6,138.6,130.0,129.8,129.2,128.6,128.5,127.6,78.8,73.4,69.4,67.0,54.9,48.4,48.1,44.1,44.1,42.7,42.6,42.3,39.6,38.6,36.1,33.6,33.5,29.4,27.6,27.5,26.5,25.1,24.6,19.1,18.3,17.9,17.2,14.9.
[0164] Embodiment 13:
[0165] Synthesis of compound 13:
[0166] 2-Fluorobenzylamine was replaced with phenethylamine, and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography, and the eluent was: petroleum ether: ethyl acetate = 2: 1 to 1: 3 (v / v), and finally compound 13 (13.5 mg) was obtained.
[0167] The structure of compound 13 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.39 , Fig.40 and Fig.41 , the characterization data are as follows:
[0168] MS (m / z): 630.4 [M+Na] + .
[0169] 1H-NMR (600MHz, C5D5N):δ H 8.20(1H,d,J=8.4Hz),7.71(1H,d,J=8.3Hz),7.64(1H,t,J=7.3Hz),7.42(1H,t,J=7.6Hz),6.3 0(1H,s),6.05(1H,s),5.82(1H,s),5.58(1H,s),5.50(1H,s),4.21-4.28(4H,m),3.75(1H,d,J =9.8Hz),3.25(1H,m),2.79(1H,s),2.27-2.34(3H,m),2.02-2.19(8H,m),1.76-1.88(4H,m),1 .64(3H,s),1.43-1.57(5H,m),1.37(3H,s),1.14(3H,d,J=6.48Hz),1.11(6H,s),1.09(3H,s).
[0170] 13 C-NMR (150MHz, C5D5N):δ C 175.2,144.6,138.6,130.0,129.8,129.6,127.4,127.3,125.7,78.7,73.1,69.3,66.9,55.0,50.2,48.1,44.1,42.8,42.4,41.0,40.7,39.4,38.8,38.6,35.9,33.8,33.7,29.9,27.1,27.0,26.5,24.7,24.7,19.1,18.3,17.9,17.1,14.9.
[0171] Embodiment 14:
[0172] Synthesis of compound 14:
[0173] 2-Fluorobenzylamine was replaced with tryptamine and the product was synthesized according to the synthesis method of compound 1. The product was purified by silica gel column chromatography with the eluent being: petroleum ether:ethyl acetate=2:1-1:3 (v / v) to finally obtain compound 14 (6 mg).
[0174] The structure of compound 14 was confirmed by mass spectrometry, H NMR spectrum and C spectrum data. Fig.42 , Fig.43 and Fig.44 , the characterization data are as follows:
[0175] MS (m / z): 669.4 [M+Na] + .
[0176] 1 H-NMR(600MHz,C5D5N):δ H 8.20(1H,d,J=8.4Hz),7.71(1H,d,J=8.3Hz),7.64(1H,t,J=7.3Hz),7.42(1H,d,J=7.7Hz),6.30(1H,s),6.05(1H,s),5.81(1H,s),5.59(1H,s),5.50(1H,s),4.21-4.30(4H,m),3.75(1H,d,J=9.8Hz),3.26(1H,dt,J=13.6,4.3Hz),2.79(1H,s),2.28-2.34(3H,m),2.10-2.19(8H,m),1.77-1.89(4H,s),1.65(3H,s),1.41-1.50(5H,m),1.37(3H,s),1.14(3H,d,J=6.48Hz),1.11(6H,s),1.09(3H,s).
[0177] 13 C-NMR(150MHz,C5D5N):δ C 175.1,144.5,138.5,129.9,129.8,129.5,125.5,124.2,123.5,121.1,109.0,78.6,73.0,69.3,66.9,54.8,50.2,48.4,48.3,44.1,42.7,42.5,42.3,40.9,38.7,38.5,33.6,33.6,29.8,27.5,27.0,26.9,26.4,25.0,24.6,19.0,18.2,17.8,17.0,14.8。
Claims
1. An anti-Alzheimer's disease compound, characterized in that The compound is an amidated derivative of the sapogenin of Rosa laevigata, and is a new RLMS derivative with structural modification of the COOH at position 28. The structural formula is any one of the following:
2. An anti-Alzheimer's disease compound according to claim 1, characterized in that: The preparation method of the compound is as follows: dissolving in 1-2 mL of DMF, reacting the rosa sapogenin with a reagent at a ratio of 1:1.5-2.5 for 0-1 h at 0-35° C., separating the product by column chromatography to obtain a rosa sapogenin structure-modified compound, wherein the reagent is a conventional reagent selected according to the structural characteristics of the compound.
